Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer

Cancer Cell(2020)10.1016/j.ccell.2020.08.016Source: DataRank Database

Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer is a research paper published in Cancer Cell (2020). On theSindex it has a DataRank of 0. It has been cited 54 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access54 citations

Download PDF

Cite:

Linked data & code

cellosaurus hpa uniprot ega nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (29 grants)OA: hybridTopics (64)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, PMC)Annotations (6)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (24)

Alan J. Wright ORCID,Paula D’Santos,De‐En Hu ORCID,Richard L. Hesketh ORCID,Yaniv Lubling ORCID

Live enrichment

PubMed:32976773 PMC:PMC7562820

National Institutes of Health

Grant: R01CA190642-01

National Institutes of Health

Grant: P30 CA008748

Cancer Research UK

Grant: C197/A28289

Cancer Research UK

Grant: 17242

Cancer Research UK

Grant: 22310

Cancer Research UK

Grant: 28289

Cancer Research UK

Grant: C197/A16465

NCI NIH HHS

Grant: R01 CA190642

Cancer Research UK

Grant: 25006

Cancer Research UK

Grant: 29567

Cancer Research UK

Grant: 16465

Cancer Research UK

Grant: S_4073

European Commission

Grant: 260791

A European Platform for Translational Cancer Research

National Institutes of Health

Grant: 2P30CA008748-43

MOUSE GENETICS

National Institutes of Health

Grant: 5R01CA190642-05

Unraveling resistance to PI3K-alpha inhibitors in breast cancer

European Commission

Grant: 258967

Rational Therapy for Breast Cancer: Individualized Treatment for Difficult-to-Treat Breast Cancer Subtypes

GlaxoSmithKline

Pfizer

Novartis

Breast Cancer Research Foundation

Roche

Bayer

Genentech

National Science Foundation

University of Cambridge

V Foundation for Cancer Research

International Business Machines Corporation

AstraZeneca

Stand Up To Cancer

hybridLicense: CC BY

publisherhttps://api.elsevier.com/content/article/PII:S153561082030427X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S153561082030427X?httpAccept=text/plain

Unpaywallhttp://www.cell.com/article/S153561082030427X/pdf

Europe_PMChttps://europepmc.org/articles/PMC7562820

https://doi.org/10.1016/j.ccell.2020.08.016

Fields of Study

0301 basic medicine03 medical and health sciences0303 health sciences

MeSH Terms

Cell Line, TumorAnimalsMice, Inbred NODMice, KnockoutHumansMice, SCIDBreast NeoplasmsTamoxifenOxazepinesImidazolesReceptors, EstrogenAntineoplastic Combined Chemotherapy ProtocolsProtein Kinase InhibitorsMagnetic Resonance ImagingXenograft Model Antitumor AssaysDrug Resistance, NeoplasmFemaleClass I Phosphatidylinositol 3-KinasesMCF-7 CellsForkhead Box Protein M1Fulvestrant

Keywords

Lactate dehydrogenaseBreast cancerMRIBiomarkerFoxm1Treatment ResponseFdg-petHexokinase 2Hyperpolarized [1-(13)C]pyruvatePi3k Alpha InhibitionOther subheadings::Other subheadings::/therapeutic useClass I Phosphatidylinositol 3-KinasesOtros calificadores::Otros calificadores::/uso terapéuticoMedicaments antineoplàstics - Ús terapèuticBreast NeoplasmsMice, SCIDTÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::protocolos clínicos::protocolos antineoplásicos::protocolos de quimioterapia antineoplásica combinadaArticleMama - CàncerMice, Inbred NODCell Line, TumorAntineoplastic Combined Chemotherapy ProtocolsAnimalsHumansFulvestrantProtein Kinase InhibitorsMice, KnockoutForkhead Box Protein M1ImidazolesMagnetic Resonance ImagingXenograft Model Antitumor AssaysOxazepinesTamoxifenReceptors, EstrogenDrug Resistance, NeoplasmMCF-7 CellsFemaleENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mamaDISEASES::Neoplasms::Neoplasms by Site::Breast NeoplasmsANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Clinical Protocols::Antineoplastic Protocols::Antineoplastic Combined Chemotherapy Protocols

Sustainable Development Goals

SDG 3: 3. Good health

Metabolic imaging detects resistance to PI3K alpha inhibition mediated by persistent FOXM1 expression in ER+ breast cancer _ Raw data

10.17863/cam.55683Apollo - University of Cambridge Repository

Research Data supporting ''Metabolic imaging detects resistance to PI3K alpha inhibition mediated by persistent FOXM1 expression in ER+ breast cancer" (Matlab_pyrlac_script)

10.17863/cam.62058Apollo - University of Cambridge Repository